Matthew M Heeney MD (He/Him)
Associate Professor of Pediatrics, Harvard Medical School
Join to View Full Profile
300 Longwood AveBoston, MA 02115
Phone+1 617-919-3242
Fax+1 617-730-0641
Dr. Heeney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Heeney is a pediatric hematologist/oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and Boston Medical Center. He received his medical degree from University of Calgary Faculty of Medicine and has been in practice 22 years. He also speaks multiple languages, including French. He is experienced in hemochromatosis, iron deficiency anemia, pediatric hematology / oncology, sideroblastic anemia, and pediatric sickle cell anemia.
Education & Training
Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1999 - 2002
McGill University Faculty Medicine HospitalPediatrics, 1995 - 1999
University of Calgary Faculty of MedicineClass of 1995
Certifications & Licensure
MA State Medical License 2002 - 2027
VA State Medical License 2002 - 2004
NC State Medical License 1999 - 2002
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis Start of enrollment: 2005 Apr 01
- Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Start of enrollment: 2005 Aug 01
- Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria.Sarah Ducamp, Min Wu, Juan Putra, Dean R Campagna, Yi Xiang
The Journal of Clinical Investigation. 2025-09-16 - A xeno-free red blood cell differentiation formula models Sickle Cell Disease from somatically-sourced patient iPSCs.Ashlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, Samuel Landry, Melissa A Kinney
Experimental Hematology. 2025-09-14 - Screen of the ReFRAME Compound Library for Therapeutic Agents to Prevent Red Blood Cell Sickling Using an Improved High Throughput Sickling Assay.Akito Nakagawa, Kaycie Morwood, Kristen Johnson, Lorenzo Berra, Lauren Boal
ACS Omega. 2025-04-29
Journal Articles
- The Phenotypic Spectrum of Germline YARS2 Variants: From Isolated Sideroblastic Anemia to Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia 2Matthew M Heeney, Gregory A Hale, David P Steensma, Mark D Fleming, Colin A Sieff, Lee M Hilliard, Sylvia S Bottomley, Janet L Kwiatkowski, Haematologica
Press Mentions
Researchers Report New Opportunities to Improve Quality of Life for People with Non-Malignant Blood DisordersDecember 7th, 2024
A Sickle Cell First: Base Editing, a New Form of Gene Therapy, Leaves Patient Feeling 'More Than Fine'December 7th, 2024- VIDEO: Dosing Evaluation Trial Aims to ‘Broaden the Label’ for Sickle Cell TreatmentDecember 20th, 2021
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
